DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer letters"
DOI: 10.1016/j.canlet.2022.215608
Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is a serious hematologic malignancy and glucocorticoid resistance is the main recurrent cause for a high relapsed and death rate. Here, we proposed an effective therapeutic regimen of combining gamma-secretase… read more here.
Keywords: cell acute; peptide modified; dt7 peptide; leukemia ... See more keywords